Clinical trials: Patients With Locally Advanced Rectal Cancer
Colorectal Cancer
PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery
RATIONALE: Diagnostic procedures, such as PET and CT scans, may improve the ability to detect the extent of locally advanced primary rectal cancer and may also help to measure a patient's response to treatment.
- Trial name
- NCT00004891
- Testing
- chemotherapy, computed tomography, conventional surgery
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cyclosporine may relieve the diarrhea caused by irinotecan.
- Trial name
- NCT00003950
- Testing
- cyclosporine, CPT-11
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Colorectal Cancer, Gastric Cancer
Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers
It is planned to study the effectiveness of low-dose immunotherapy (IT) nivolumab 40 mg for either 2 courses of therapy or 6 courses as preoperative therapy in patients with dMMR/MSI locally advanced CRC.
- Trial name
- NIVO402025 (NCT07542262)
- Testing
- Low-dose nivolumab, Low-dose nivolumab with/without chemotherapy, Low-dose nivolumab combined with chemotherapy
- Where
- Russia
- Volunteers
- 128 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Rectal Cancer
Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy in Combination With Bevacizumab-FOLFOX
In this phase I trial neoadjuvant CCRT combining IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and BV-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens is planned for 15 locally advanced…
- Trial name
- NCT01395667
- Testing
- CCRT
- Where
- Taiwan
- Volunteers
- 15 people
- Sponsor
- National Taiwan University Hospital
Metastatic Colorectal Cancer
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
This will be a multicenter, open-label study enrolling a total of up to 23 patients.
- Trial name
- NCT00851136
- Testing
- bevacizumab, FOLFOX, PRO95780
- Volunteers
- 9 people
- Sponsor
- Genentech, Inc.
Colon Rectal Cancer
Immunotherapy In Locally Advanced Rectal Cancer
Preoperative CTRT is considered the standard of care in the management of LARC. Preoperative CTRT approach results in significant tumor downstaging and local control with a complete pathological response rate of about 15% even if…
- Trial name
- AVANA (NCT03854799)
- Testing
- Avelumab, Capecitabine, EXTERNAL---BEAM IRRADIATION 50.4 GY
- Where
- Italy
- Volunteers
- 101 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Locally Advanced Resectable Rectal Cancer
Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer
This prospective, single-arm, exploratory clinical study aims to evaluate the efficacy and safety of short-course radiotherapy (SCRT) sequentially followed by adebrelimab combined with chemotherapy as an organ-preservation…
- Trial name
- NCT07905950
- Testing
- Adebrelimab
- Where
- China
- Volunteers
- 155 people
- Sponsor
- Henan Cancer Hospital
Rectal Cancer
Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer
The aims of the trial are (1) to determine the tolerability rate in the setting of a multi-centre study and (2) to determine secondary tolerability endpoints, toxicity rates and complete pathologic response rate in patients with…
- Trial name
- PROArCT (NCT01013805)
- Testing
- External Beam Radiotherapy, Oxaliplatin, Fluorouracil
- Where
- Australia
- Volunteers
- 41 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Rectal Cancer
Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer
The standard treatment for stage 2/3 rectal cancer is neoadjuvant 5-Fu based chemoradiation. However, preoperative radiation cause kinds of adverse events, some were irreversible. And the survival benefit was not obvious.
- Trial name
- FORTUNE (NCT02217020)
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Response Assessment by Circulating Tumor DNA in Patients With Locally Advanced Rectal Cancer
This is a single-arm observational study to determine the feasibility of assessing tumor response utilizing Circulating tumor DNA (ctDNA) in patients of with locally advanced rectal cancer (LARC) undergoing standard-of-care total…
- Trial name
- NCT04670588
- Testing
- Circulating tumor DNA(ctDNA) level measurement
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Rectal Cancer
Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
Preoperative chemoradiation leads to increased pelvic control and overall survival, but both distant and local disease control remain problematic in locally advanced rectal cancer patients.
- Trial name
- NCT00113230
- Testing
- Avastin (Bevacizumab, RHUMAB VEGF), Capecitabine, Radiation Therapy
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Colon Adenocarcinoma, ERBB2 Gene Amplification
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it…
- Conditions
- Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma
- Trial name
- NCT03365882
- Testing
- Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 798 sites in United States, Puerto Rico
- Volunteers
- 240 people
- Sponsor
- SWOG Cancer Research Network
Rectal Cancer, Rectal Adenocarcinoma
SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
This study aims to evaluate the efficacy and safety of short-course radiotherapy combined with CAPOX plus bevacizumab with or without a PD-1 inhibitor in patients with locally advanced rectal cancer (LARC).
- Conditions
- Rectal Cancer, Rectal Adenocarcinoma, Rectal Cancer, Radiotherapy, Rectal Cancer Patients
- Trial name
- NCT07198165
- Testing
- PD-1 inhibitor based immunotherapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Ruijin Hospital
Colorectal Cancer
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.
- Trial name
- NCT04468607
- Testing
- BLYG8824A
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.
Anal Cancer
A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma
SCARCE is a non-comparative randomized, 2:1 phase II study. The purpose of this study is to assess the progression-free survival rate at 12 months. (evaluation according with RECISTv1.1 criteria).
- Trial name
- SCARCE (NCT03519295)
- Testing
- MPDL3280A, mDCF
- Where
- 31 sites in France
- Volunteers
- 97 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Rectal Cancer
Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer
The investigators planned a phase I study of preoperative CRT with capecitabine plus temozolomide inpatients with locally advanced resectable rectal cancer: 1) the role of temozolomide as a radiosensitizer has been well…
- Trial name
- NCT01781403
- Testing
- Temozolomide
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Asan Medical Center
Rectal Cancer
Preoperative IMRT With Concurrent High-dose Vitamin C and mFOLFOX6 in Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the safety and efficacy of preoperative chemoradiotherapy (IMRT) with concurrent high-dose intravenous vitamin C and mFOLFOX6 in locally advanced rectal cancer patients.
- Trial name
- CORT (NCT04801511)
- Testing
- Vitamin C
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhou Fuxiang
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 36 sites in United States, Australia and 8 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
BRAF V600E Negative, KRAS Gene Mutation Negative
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
This phase II trial how well regorafenib and anti-EGFR therapy (cetuximab or panitumumab) works for the treatment of patients with colorectal cancer that cannot be removed by surgery (unresectable), has spread to nearby tissue or…
- Conditions
- BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT04117945
- Testing
- Cetuximab, Irinotecan, Panitumumab
- Where
- 15 sites in United States
- Volunteers
- 22 people
- Sponsor
- Academic and Community Cancer Research United
Rectal Cancer
A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer
To assess the efficacy and safety of pre-operative capecitabine and oxaliplatin followed by capecitabine with concurrent radiotherapy followed by post-operative capecitabine in the treatment of patients with locally advanced or…
- Trial name
- NCT00220051
- Testing
- Oxaliplatin, Capecitabine, Pre operative radiotherapy, Surgical Resection
- Volunteers
- 109 people
- Sponsor
- Royal Marsden NHS Foundation Trust